Baxter Hlthcare Company Profile

What is the competitive landscape for BAXTER HLTHCARE

BAXTER HLTHCARE has two hundred and twenty-four approved drugs.

There are thirty-one US patents protecting BAXTER HLTHCARE drugs. There are three tentative approvals on BAXTER HLTHCARE drugs.

There are seventy-two patent family members on BAXTER HLTHCARE drugs in twenty countries and three hundred and forty supplementary protection certificates in seventeen countries.

Summary for Baxter Hlthcare

International Patents:	72
US Patents:	31
Tradenames:	306
Ingredients:	136
NDAs:	224

Drugs and US Patents for Baxter Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	sodium chloride	SOLUTION;INJECTION	020178-002	Dec 7, 1992	AP	RX	Yes	No
Baxter Hlthcare	TRAVAMULSION 20%	soybean oil	INJECTABLE;INJECTION	018758-001	Feb 15, 1983		DISCN	No	No
Baxter Hlthcare	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	018649-006	Nov 13, 1985		DISCN	No	No
Baxter Hlthcare Corp	GRANISETRON HYDROCHLORIDE	granisetron hydrochloride	INJECTABLE;INJECTION	078197-001	Dec 31, 2007		DISCN	No	No
Baxter Hlthcare	PREMASOL 10% IN PLASTIC CONTAINER	amino acids	INJECTABLE;INJECTION	075880-002	Jun 19, 2003		RX	No	No

Expired US Patents for Baxter Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-003	Oct 10, 1992	4,220,660
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-004	Oct 10, 1992	4,882,452
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-001	Dec 30, 1988	4,882,452
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	4,031,894
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	3,732,340

Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags		2014-01-31
	Inhalation	99.90%		2008-09-11

International Patents for Baxter Hlthcare Drugs

Country	Patent Number	Estimated Expiration
Japan	6276828
Canada	3174640
South Korea	101633479
Japan	6276828
Australia	2021233893

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3752510	202540037	Slovenia		PRODUCT NAME: VANZACAFTOR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY A CALCIUM SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/25/1943; DATE OF NATIONAL AUTHORISATION: 20250630; AUTHORITY FOR NATIONAL AUTHORISATION: EU
1856135	CR 2020 00018	Denmark		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
1856135	2020/017	Ireland		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113
2957286	132019000000021	Italy		PRODUCT NAME: PATIROMER SORBITEX CALCIUM E QUALSIASI SUO SALE O DERIVATO(VELTASSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1179, 20170721
0809498	SPC/GB10/012	United Kingdom		PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Baxter Hlthcare
• Baxter Hlthcare Corp